Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China flag China · Delayed Price · Currency is CNY
4.710
-0.180 (-3.68%)
Nov 13, 2026, 3:00 PM CST

SHA:603567 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
257.27768.472,6773,0844,1994,120
Other Revenue
29.1228.8626.9354.1114.686.5
286.39797.342,7043,1384,2144,127
Revenue Growth
-82.04%-70.51%-13.84%-25.53%2.12%21.24%
Cost of Revenue
992.951,1911,3341,8463,5392,829
Gross Profit
-706.56-393.51,3701,292675.251,298
Selling, General & Admin
264.82359.68575.22979.01915.17952.16
Research & Development
34.2246.3537.9980.2270.9555.23
Other Operating Expenses
60.8323.9936.0343.79-64.36-24.14
Operating Expenses
474.21729.74767.061,107891.961,028
Operating Income
-1,181-1,123602.9185.52-216.71270.38
Interest Expense
-24.43-139-137.09-135.41-138.68-144.79
Interest & Investment Income
31.2137.7422.69471.6838.06251.32
Currency Exchange Gain (Loss)
-----0-0
Other Non Operating Income (Expenses)
-701.95-378.299.22-88.5926.83-22.32
EBT Excluding Unusual Items
-1,876-1,603497.73433.2-290.5354.6
Impairment of Goodwill
----2.4-1.28-
Gain (Loss) on Sale of Investments
-15.77-11.95-9.690.6-1.75-0.15
Gain (Loss) on Sale of Assets
-10.26-0.85-2.31-0.2639.33-1.11
Asset Writedown
156.16-14.48--1.51--0.09
Other Unusual Items
14.522.6737.7548.72552.68101.49
Pretax Income
-1,731-1,627523.47478.35298.48454.75
Income Tax Expense
-255.12-257.4787.0810.76107.55121.99
Earnings From Continuing Operations
-1,476-1,370436.39467.59190.93332.76
Minority Interest in Earnings
0.333.41.825.15-5.49-0.66
Net Income
-1,476-1,367438.22472.74185.44332.1
Net Income to Common
-1,476-1,367438.22472.74185.44332.1
Net Income Growth
---7.30%154.93%-44.16%-23.88%
Shares Outstanding (Basic)
940940940939941865
Shares Outstanding (Diluted)
940940940940941865
Shares Change
-0.08%-0.01%-0.01%-0.14%8.87%1.82%
EPS (Basic)
-1.57-1.450.470.500.200.38
EPS (Diluted)
-1.57-1.450.470.500.200.38
EPS Growth
---7.30%155.28%-48.71%-25.24%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
198.19253.57-24.84-573.38-731.07-882.57
Free Cash Flow Per Share
0.210.27-0.03-0.61-0.78-1.02
Dividend Per Share
--0.1500.2000.0280.106
Dividend Growth
---25.00%614.29%-73.58%-
Gross Margin
-246.72%-49.35%50.67%41.18%16.02%31.45%
Operating Margin
-412.30%-140.88%22.30%5.91%-5.14%6.55%
Profit Margin
-515.33%-171.39%16.21%15.06%4.40%8.05%
Free Cash Flow Margin
69.21%31.80%-0.92%-18.27%-17.35%-21.39%
EBITDA
-993.16-956.37742.12364.32-59.75405.93
EBITDA Margin
--119.95%27.45%11.61%-1.42%9.84%
D&A For EBITDA
187.62166.88139.22178.8156.95135.55
EBIT
-1,181-1,123602.9185.52-216.71270.38
EBIT Margin
--140.88%22.30%5.91%-5.14%6.55%
Effective Tax Rate
--16.63%2.25%36.03%26.82%
Revenue as Reported
-798.062,7073,1444,2194,130
Advertising Expenses
-12.1415.9410.423.572.17